Concomitant Driver Mutations in Advanced Stage Non-Small-Cell Lung Cancer of Adenocarcinoma Subtype with Activating EGFR-Mutation

被引：0
|
作者：
Sorensen, Jens Benn [1 ]
Grauslund, Morten [2 ]
Melchior, Linea [2 ]
Jakobsen, Jan [1 ]
Santoni-Rugiu, Eric [2 ]
机构：
[1] Natl Univ Hosp, Finsen Ctr, Dept Oncol, Copenhagen, Denmark
[2] Natl Univ Hosp, Dept Pathol, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
EGFR mutation; next generation sequencing; MET amplification; MET expression;
D O I：
10.1016/j.jtho.2016.11.635
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.02-051
引用
收藏
页码：S518 / S519
页数：3
相关论文
共 50 条
  • [1] Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
    Carlisle, Jennifer W.
    Ramalingam, Suresh S.
    [J]. FUTURE ONCOLOGY, 2019, 15 (08) : 805 - 816
  • [2] Concomitant EGFR Mutation and ALK Rearrangement in Non-Small-Cell Lung Cancer
    Chen, R.
    Zhang, X.
    Wu, Y.
    Chen, H.
    Zhou, Q.
    Su, J.
    Tu, H.
    Xie, Z.
    Zhong, W.
    Yang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2225 - S2226
  • [3] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [4] EGFR mutations in non-small-cell lung cancer
    Hung, Jung-Jyh
    Jeng, Wen-Juei
    Hsu, Wen-Hu
    Liu, Jung-Sen
    Wu, Yu-Chung
    [J]. LANCET ONCOLOGY, 2010, 11 (05): : 412 - 413
  • [5] Clinical Outcome and Toxicity Profiles of Patients with EGFR-mutation Positive Non-Small-Cell Lung Cancer
    Munawar, K.
    Sheikh, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S621 - S622
  • [6] Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
    Sara Simonetti
    Miguel Angel Molina
    Cristina Queralt
    Itziar de Aguirre
    Clara Mayo
    Jordi Bertran-Alamillo
    José Javier Sanchez
    Jose Luis Gonzalez-Larriba
    Ulpiano Jimenez
    Dolores Isla
    Teresa Moran
    Santiago Viteri
    Carlos Camps
    Rosario Garcia-Campelo
    Bartomeu Massuti
    Susana Benlloch
    Santiago Ramon y Cajal
    Miquel Taron
    Rafael Rosell
    [J]. Journal of Translational Medicine, 8
  • [7] Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
    Simonetti, Sara
    Angel Molina, Miguel
    Queralt, Cristina
    de Aguirre, Itziar
    Mayo, Clara
    Bertran-Alamillo, Jordi
    Javier Sanchez, Jose
    Luis Gonzalez-Larriba, Jose
    Jimenez, Ulpiano
    Isla, Dolores
    Moran, Teresa
    Viteri, Santiago
    Camps, Carlos
    Garcia-Campelo, Rosario
    Massuti, Bartomeu
    Benlloch, Susana
    Ramon y Cajal, Santiago
    Taron, Miquel
    Rosell, Rafael
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [8] Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer
    Clopes, Ana
    Gasol, Montse
    Cajal, Rosana
    Segu, Luis
    Crespo, Ricard
    Mora, Ramon
    Simon, Susana
    Cordero, Luis A.
    Calle, Candela
    Gilabert, Antoni
    Germa, Josep R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 1 - 7
  • [9] New driver mutations in non-small-cell lung cancer
    Pao, William
    Girard, Nicolas
    [J]. LANCET ONCOLOGY, 2011, 12 (02): : 175 - 180
  • [10] Nivolumab in non-small-cell lung cancer with EGFR mutation
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Yasuda, Y.
    Funazo, T.
    Hirai, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (03) : 777 - 778
12345